世界の黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3523 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（黄斑変性症治療薬、糖尿病性網膜症治療薬）、用途別市場規模（50〜60歳、60〜70歳、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の市場動向 ・企業の競争状況、市場シェア ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の種類別市場規模（黄斑変性症治療薬、糖尿病性網膜症治療薬） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の用途別市場規模（50〜60歳、60〜70歳、その他） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan） ・結論

Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.

Market Analysis and Insights: Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market
The global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market.

Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Scope and Market Size
Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Macular Degeneration Drugs
Diabetic Retinopathy Drugs

Segment by Application
50-60 Years Old
60-70 Years Old
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Macular Degeneration Drugs
1.2.3 Diabetic Retinopathy Drugs
1.3 Market by Application
1.3.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 50-60 Years Old
1.3.3 60-70 Years Old
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Perspective (2016-2027)
2.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Growth Trends by Regions
2.2.1 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Industry Dynamic
2.3.1 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Trends
2.3.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Drivers
2.3.3 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Challenges
2.3.4 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players by Revenue
3.1.1 Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players by Revenue (2016-2021)
3.1.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue
3.4 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Concentration Ratio
3.4.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue in 2020
3.5 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players Head office and Area Served
3.6 Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Solution and Service
3.7 Date of Enter into Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Breakdown Data by Type
4.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Historic Market Size by Type (2016-2021)
4.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Type (2022-2027)

5 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Breakdown Data by Application
5.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Historic Market Size by Application (2016-2021)
5.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2016-2027)
6.2 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type
6.2.1 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021)
6.2.2 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027)
6.2.3 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2027)
6.3 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application
6.3.1 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021)
6.3.2 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027)
6.3.3 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2027)
6.4 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country
6.4.1 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2016-2021)
6.4.2 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2016-2027)
7.2 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type
7.2.1 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021)
7.2.2 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027)
7.2.3 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2027)
7.3 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application
7.3.1 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021)
7.3.2 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027)
7.3.3 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2027)
7.4 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country
7.4.1 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2016-2021)
7.4.2 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2016-2027)
8.2 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type
8.2.1 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application
8.3.1 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Region
8.4.1 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2016-2027)
9.2 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type
9.2.1 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2027)
9.3 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application
9.3.1 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2027)
9.4 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country
9.4.1 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2016-2027)
10.2 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type
10.2.1 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application
10.3.1 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country
10.4.1 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
11.1.4 Novartis Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Details
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
11.2.4 Bayer Healthcare Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
11.2.5 Bayer Healthcare Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
11.3.4 Roche Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Neurotech Pharmaceuticals
11.4.1 Neurotech Pharmaceuticals Company Details
11.4.2 Neurotech Pharmaceuticals Business Overview
11.4.3 Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
11.4.4 Neurotech Pharmaceuticals Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
11.4.5 Neurotech Pharmaceuticals Recent Development
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Details
11.5.2 Regeneron Pharmaceuticals Business Overview
11.5.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
11.5.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
11.5.5 Regeneron Pharmaceuticals Recent Development
11.6 Allergan
11.6.1 Allergan Company Details
11.6.2 Allergan Business Overview
11.6.3 Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
11.6.4 Allergan Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
11.6.5 Allergan Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Macular Degeneration Drugs
Table 3. Key Players of Diabetic Retinopathy Drugs
Table 4. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Regions (2016-2021)
Table 8. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Regions (2022-2027)
Table 10. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Trends
Table 11. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Drivers
Table 12. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Challenges
Table 13. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Restraints
Table 14. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Players (2016-2021)
Table 16. Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs as of 2020)
Table 17. Ranking of Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Solution and Service
Table 21. Date of Enter into Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Type (2016-2021)
Table 25. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Application (2016-2021)
Table 29. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 61. Novartis Company Details
Table 62. Novartis Business Overview
Table 63. Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product
Table 64. Novartis Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021) & (US$ Million)
Table 65. Novartis Recent Development
Table 66. Bayer Healthcare Company Details
Table 67. Bayer Healthcare Business Overview
Table 68. Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product
Table 69. Bayer Healthcare Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021) & (US$ Million)
Table 70. Bayer Healthcare Recent Development
Table 71. Roche Company Details
Table 72. Roche Business Overview
Table 73. Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product
Table 74. Roche Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021) & (US$ Million)
Table 75. Roche Recent Development
Table 76. Neurotech Pharmaceuticals Company Details
Table 77. Neurotech Pharmaceuticals Business Overview
Table 78. Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product
Table 79. Neurotech Pharmaceuticals Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021) & (US$ Million)
Table 80. Neurotech Pharmaceuticals Recent Development
Table 81. Regeneron Pharmaceuticals Company Details
Table 82. Regeneron Pharmaceuticals Business Overview
Table 83. Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product
Table 84. Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021) & (US$ Million)
Table 85. Regeneron Pharmaceuticals Recent Development
Table 86. Allergan Company Details
Table 87. Allergan Business Overview
Table 88. Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product
Table 89. Allergan Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021) & (US$ Million)
Table 90. Allergan Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type: 2020 VS 2027
Figure 2. Macular Degeneration Drugs Features
Figure 3. Diabetic Retinopathy Drugs Features
Figure 4. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application: 2020 VS 2027
Figure 5. 50-60 Years Old Case Studies
Figure 6. 60-70 Years Old Case Studies
Figure 7. Other Case Studies
Figure 8. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Report Years Considered
Figure 9. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Regions: 2020 VS 2027
Figure 12. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Regions (2022-2027)
Figure 13. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Players in 2020
Figure 14. Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue in 2020
Figure 16. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Type (2016-2021)
Figure 17. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Type (2022-2027)
Figure 18. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2016-2027)
Figure 20. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2016-2027)
Figure 21. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Country (2016-2027)
Figure 22. United States Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2016-2027)
Figure 26. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2016-2027)
Figure 27. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Country (2016-2027)
Figure 28. Germany Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Region (2016-2027)
Figure 38. China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2016-2027)
Figure 46. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2016-2027)
Figure 47. Latin America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Country (2016-2027)
Figure 48. Mexico Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Country (2016-2027)
Figure 54. Turkey Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Novartis Revenue Growth Rate in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
Figure 58. Bayer Healthcare Revenue Growth Rate in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
Figure 59. Roche Revenue Growth Rate in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
Figure 60. Neurotech Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
Figure 61. Regeneron Pharmaceuticals Revenue Growth Rate in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
Figure 62. Allergan Revenue Growth Rate in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

---